Vitrafy Raises $30m to Scale Guardion, Target US Blood Market

Vitrafy Life Sciences (ASX: VFY) has raised $30 million through an institutional placement to expand manufacturing of its Guardion cryopreservation devices and expand its US operations. The company issued about 11.54 million new shares at $2.60 each, a 31.6% discount to the last close of $3.80 on June 9 and an 8.8% discount to the 15-day volume-weighted average price of $2.851.

The raise follows recent progress in the US blood market, where Vitrafy is positioning its technology against a looming replacement cycle. Existing red blood cell processing equipment and glycerol-based cryoprotectants are due to be phased out by the end of 2027. No approved replacement for the current frozen red blood cell infrastructure exists, creating a window for Vitrafy's platform.

The US blood network faces chronic platelet shortages and short shelf lives. Platelets have a shelf life of less than seven days at room temperature, which forces blood centres to discard a significant portion of the approximately 2.6 million units collected annually. The estimated $280 million in yearly wastage represents a direct cost to the healthcare system. Vitrafy's platelet preservation technology has shown 94.4% post-thaw recovery in Phase I and Phase II US Army studies, exceeding European and US benchmarks cited by the company.

Vitrafy will allocate $15 million of the placement proceeds to building its Guardion device fleet, $8 million to US sales and operations, $5.2 million to working capital, and $1.8 million to raising costs. Eligible shareholders in Australia and New Zealand can participate in a non-underwritten share purchase plan targeting up to $2 million at the same issue price. The SPP is not underwritten, so the full $2 million may not be raised.

Guardion is the hardware component of an integrated cryopreservation platform that includes controlled-rate freezing, LifeChain cloud software, point-of-care thawing equipment, and recurring-use consumables. The company's managed-service model charges monthly fees for hardware, software, and support, plus consumable revenue tied to the number of cryopreservation cycles performed. That recurring revenue stream is already running through its animal reproduction business, which has a revenue-generating agreement with IMV Technologies for aquaculture, bovine, and other species. The animal reproduction business provides a commercial template for the US blood market, with recurring revenue from consumables and service fees.

The company's recently announced partnership with Vitalant will begin with two service packages at Vitalant's research institute, targeting next-generation red blood cell solutions for rare blood programs and stockpiling. Vitrafy is also pursuing cell and gene therapy applications, where preserving high-value biological materials with minimal viability loss could support manufacturers and blood centres.

Managing director and CEO Brent Owens said the funding would support the next stage of commercial expansion. "With recent commercial milestones being achieved in the US blood market, we are more increasingly confident about the growth opportunities for the company," he said. "This capital enables us to scale Guardion manufacturing to meet demand and accelerate the growth in our US operations as we progress towards our commercialisation and medical device registration milestones."

Vitrafy is targeting Guardion medical device registration in the first half of the 2027 financial year and continues engagement with the US Food and Drug Administration on pathways for red blood cell applications. The company expects to issue the new shares from the placement and the SPP in due course.